Mutual of America Capital Management LLC Trims Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Mutual of America Capital Management LLC trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,811 shares of the medical research company’s stock after selling 3,535 shares during the period. Mutual of America Capital Management LLC’s holdings in Edwards Lifesciences were worth $5,242,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at $555,939,000. Assenagon Asset Management S.A. grew its position in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after purchasing an additional 3,506,886 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after acquiring an additional 2,606,950 shares during the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $109,490,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 0.3 %

Shares of NYSE EW opened at $71.37 on Tuesday. The firm’s 50 day moving average price is $72.58 and its 200-day moving average price is $70.32. The company has a market cap of $42.09 billion, a PE ratio of 10.24, a P/E/G ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock worth $2,799,104 over the last quarter. Company insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of a number of research analyst reports. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.